The granulocyte progenitor stage is a key target of irf8-mediated regulation of myeloid-derived suppressor cell production

Journal of Immunology

Volumn 198, Issue 10, 2017, Pages 4129-4139

  Netherby, Colleen S ^a   Messmer, Michelle N ^a   Burkard Mandel, Lauren ^a   Colligan, Sean ^a   Miller, Austin ^a   Gomez, Eduardo Cortes ^a   Wang, Jianmin ^a   Nemeth, Michael J ^a   Abrams, Scott I ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HOMOZYGOSITY; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; MYELOPOIESIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BONE MARROW CELL; CELL PROLIFERATION; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; GRANULOCYTE PRECURSOR; HEMATOPOIESIS; HUMAN; IMMUNOLOGY; METABOLISM; MONOCYTE; NEUTROPHIL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE PRECURSOR CELLS; GRANULOCYTES; HEMATOPOIESIS; HUMANS; INTERFERON REGULATORY FACTORS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MONOCYTES; MYELOID CELLS; MYELOID-DERIVED SUPPRESSOR CELLS; MYELOPOIESIS; NEUTROPHILS;

EID: 85019698028     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601722     Document Type: Article

References (52)

1. Messmer, M. N., C. S. Netherby, D. Banik, and S. I. Abrams. 2015. Tumorinduced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64: 1-13.
2. Shoenfeld, Y., A. Tal, S. Berliner, and J. Pinkhas. 1986. Leukocytosis in non hematological malignancies-a possible tumor-associated marker. J. Cancer Res. Clin. Oncol. 111: 54-58.
3. Gabrilovich, D. I., V. Bronte, S. H. Chen, M. P. Colombo, A. Ochoa, S. Ostrand- Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67: 425.
4. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
5. Suzuki, E., V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda. 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 6713-6721.
6. Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
7. Sevko, A., T. Michels, M. Vrohlings, L. Umansky, P. Beckhove, M. Kato, G. V. Shurin, M. R. Shurin, and V. Umansky. 2013. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190: 2464-2471.
8. Waight, J. D., C. Netherby, M. L. Hensen, A. Miller, Q. Hu, S. Liu, P. N. Bogner, M. R. Farren, K. P. Lee, K. Liu, and S. I. Abrams. 2013. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 123: 4464-4478.
9. Mahoney, K. M., P. D. Rennert, and G. J. Freeman. 2015. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14: 561-584.
10. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107: 4275-4280.
11. Solito, S., I. Marigo, L. Pinton, V. Damuzzo, S. Mandruzzato, and V. Bronte. 2014. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 1319: 47-65.
12. Condamine, T., J. Mastio, and D. I. Gabrilovich. 2015. Transcriptional regulation of myeloid-derived suppressor cells. J. Leukoc. Biol. 98: 913-922.
13. Abrams, S. I., C. S. Netherby, D. Y. Twum, and M. N. Messmer. 2016. Relevance of interferon regulatory factor-8 expression in myeloid-tumor interactions. J. Interferon Cytokine Res. 36: 442-453.
14. Yamamoto, R., Y. Morita, J. Ooehara, S. Hamanaka, M. Onodera, K. L. Rudolph, H. Ema, and H. Nakauchi. 2013. Clonal analysis unveils self-renewing lineagerestricted progenitors generated directly from hematopoietic stem cells. Cell 154: 1112-1126.
15. Wu, W. C., H. W. Sun, H. T. Chen, J. Liang, X. J. Yu, C. Wu, Z. Wang, and L. Zheng. 2014. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc. Natl. Acad. Sci. USA 111: 4221-4226.
16. Tamura, T., T. Nagamura-Inoue, Z. Shmeltzer, T. Kuwata, and K. Ozato. 2000. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13: 155-165.
17. Tsujimura, H., T. Nagamura-Inoue, T. Tamura, and K. Ozato. 2002. IFN consensus sequence binding protein/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage. J. Immunol. 169: 1261-1269.
18. Tamura, T., and K. Ozato. 2002. ICSBP/IRF-8: Its regulatory roles in the development of myeloid cells. J. Interferon Cytokine Res. 22: 145-152.
19. Holtschke, T., J. Löhler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. F. Waring, et al. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87: 307-317.
20. Yáñez, A., M. Y. Ng, N. Hassanzadeh-Kiabi, and H. S. Goodridge. 2015. IRF8 acts in lineage-committed rather than oligopotent progenitors to control neutrophil vs monocyte production. Blood 125: 1452-1459.
21. Wang, H., M. Yan, J. Sun, S. Jain, R. Yoshimi, S. M. Abolfath, K. Ozato, W. G. Coleman, Jr., A. P. Ng, D. Metcalf, et al. 2014. A reporter mouse reveals lineage-specific and heterogeneous expression of IRF8 during lymphoid and myeloid cell differentiation. J. Immunol. 193: 1766-1777.
22. Stewart, T. J., and S. I. Abrams. 2007. Altered immune function during longterm host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J. Immunol. 179: 2851-2859.
23. Stewart, T. J., D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams. 2009. Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J. Immunol. 183: 117-128.
24. Waight, J. D., Q. Hu, A. Miller, S. Liu, and S. I. Abrams. 2011. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6: E27690.
25. Stewart, T. J., K. M. Greeneltch, J. E. Reid, D. J. Liewehr, S. M. Steinberg, K. Liu, and S. I. Abrams. 2009. Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J. Cell. Mol. Med. 13(9B): 3939-3950.
26. Pronk, C. J., D. J. Rossi, R. Mansson, J. L. Attema, G. L. Norddahl, C. K. Chan, M. Sigvardsson, I. L. Weissman, and D. Bryder. 2007. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 1: 428-442.
27. Nemeth, M. J., D. J. Curtis, M. R. Kirby, L. J. Garrett-Beal, N. E. Seidel, A. P. Cline, and D. M. Bodine. 2003. Hmgb3: An HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation. Blood 102: 1298-1306.
28. Trapnell, C., L. Pachter, and S. L. Salzberg. 2009. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-1111.
29. Wang, L., S. Wang, and W. Li. 2012. RSeQC: Quality control of RNA-seq experiments. Bioinformatics 28: 2184-2185.
30. Anders, S., P. T. Pyl, and W. Huber. 2015. HTSeq-a python framework to work with high-throughput sequencing data. Bioinformatics 31: 166-169.
31. Love, M. I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15: 550.
32. Pulaski, B. A., and S. Ostrand-Rosenberg. 2001. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 20: Unit 20.2. doi:10.1002/0471142735. im2002s39
33. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405.
34. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12: 954-961.
35. Casbon, A. J., D. Reynaud, C. Park, E. Khuc, D. D. Gan, K. Schepers, E. Passegué, and Z. Werb. 2015. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA 112: E566-E575.
36. Koenigsmann, J., C. Rudolph, S. Sander, O. Kershaw, A. D. Gruber, L. Bullinger, B. Schlegelberger, and D. Carstanjen. 2009. Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias. Blood 113: 4690-4701.
37. Scheller, M., J. Foerster, C. M. Heyworth, J. F. Waring, J. Löhler, G. L. Gilmore, R. K. Shadduck, T. M. Dexter, and I. Horak. 1999. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood 94: 3764-3771.
38. Newman, D. M., P. S. Leung, T. L. Putoczki, S. L. Nutt, and E. Cretney. 2016. Th17 cell differentiation proceeds independently of IRF8. Immunol. Cell Biol. 94: 796-801.
39. Pu, S., B. Qin, H. He, J. Zhan, Q. Wu, X. Zhang, L. Yang, C. Qu, and Z. Zhou. 2016. Identification of early myeloid progenitors as immunosuppressive cells. Sci. Rep. 6: 23115.
40. Newman, D. M., P. S. Leung, T. L. Putoczki, S. L. Nutt, and E. Cretney. 2016. Th17 cell differentiation proceeds independently of IRF8. Immunol. Cell Biol. 94: 796-801.
41. Burchert, A., D. Cai, L. C. Hofbauer, M. K. Samuelsson, E. P. Slater, J. Duyster, M. Ritter, A. Hochhaus, R. Müller, M. Eilers, et al. 2004. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and downregulates bcl-2. Blood 103: 3480-3489.
42. Gabriele, L., J. Phung, J. Fukumoto, D. Segal, I. M. Wang, P. Giannakakou, N. A. Giese, K. Ozato, and H. C. Morse, III. 1999. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. [Published erratum appears in 1999 J. Exp. Med. 190: 1722.] J. Exp. Med. 190: 411-421.
43. Hu, X., K. Bardhan, A. V. Paschall, D. Yang, J. L. Waller, M. A. Park, A. Nayak- Kapoor, T. A. Samuel, S. I. Abrams, and K. Liu. 2013. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J. Biol. Chem. 288: 19103-19115.
44. Orkin, S. H., and L. I. Zon. 2002. Hematopoiesis and stem cells: Plasticity versus developmental heterogeneity. Nat. Immunol. 3: 323-328.
45. Kurotaki, D., M. Yamamoto, A. Nishiyama, K. Uno, T. Ban, M. Ichino, H. Sasaki, S. Matsunaga, M. Yoshinari, A. Ryo, et al. 2014. IRF8 inhibits C/EBPa activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. Nat. Commun. 5: 4978.
46. Feinberg, M. W., A. K. Wara, Z. Cao, M. A. Lebedeva, F. Rosenbauer, H. Iwasaki, H. Hirai, J. P. Katz, R. L. Haspel, S. Gray, et al. 2007. The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J. 26: 4138-4148.
47. Carotta, S., S. N. Willis, J. Hasbold, M. Inouye, S. H. Pang, D. Emslie, A. Light, M. Chopin, W. Shi, H. Wang, et al. 2014. The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation. J. Exp. Med. 211: 2169-2181.
48. Tamura, T., D. Kurotaki, and S. Koizumi. 2015. Regulation of myelopoiesis by the transcription factor IRF8. Int. J. Hematol. 101: 342-351.
49. Ugel, S., F. De Sanctis, S. Mandruzzato, and V. Bronte. 2015. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125: 3365-3376.
50. Yang, L., L. M. DeBusk, K. Fukuda, B. Fingleton, B. Green-Jarvis, Y. Shyr, L. M. Matrisian, D. P. Carbone, and P. C. Lin. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
51. Highfill, S. L., Y. Cui, A. J. Giles, J. P. Smith, H. Zhang, E. Morse, R. N. Kaplan, and C. L. Mackall. 2014. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6: 237ra67.
52. Kowanetz, M., X. Wu, J. Lee, M. Tan, T. Hagenbeek, X. Qu, L. Yu, J. Ross, N. Korsisaari, T. Cao, et al. 2010. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA 107: 21248-21255.